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Abstract
Background: Preeclampsia is a female-specific risk factor for the development of future cardiovascular disease.
Whether early preventive cardiovascular disease risk screenings combined with risk-based lifestyle interventions in
women with previous preeclampsia are beneficial and cost-effective is unknown.
Methods: A micro-simulation model was developed to assess the life-long impact of preventive cardiovascular screening
strategies initiated after women experienced preeclampsia during pregnancy. Screening was started at the age of 30 or 40
years and repeated every five years. Data (initial and follow-up) from women with a history of preeclampsia was used to
calculate 10-year cardiovascular disease risk estimates according to Framingham Risk Score. An absolute risk threshold
of 2% was evaluated for treatment selection, i.e. lifestyle interventions (e.g. increasing physical activity). Screening
benefits were assessed in terms of costs and quality-adjusted-life-years, and incremental cost-effectiveness ratios com-
pared with no screening.
Results: Expected health outcomes for no screening are 27.35 quality-adjusted-life-years and increase to 27.43 quality-
adjusted-life-years (screening at 30 years with 2% threshold). The expected costs for no screening are E9426 and around
E13,881 for screening at 30 years (for a 2% threshold). Preventive screening at 40 years with a 2% threshold has the
most favourable incremental cost-effectiveness ratio, i.e. E34,996/quality-adjusted-life-year, compared with other screen-
ing scenarios and no screening.
Conclusions: Early cardiovascular disease risk screening followed by risk-based lifestyle interventions may lead to small
long-term health benefits in women with a history of preeclampsia. However, the cost-effectiveness of a lifelong car-
diovascular prevention programme starting early after preeclampsia with risk-based lifestyle advice alone is relatively
unfavourable. A combination of risk-based lifestyle advice plus medical therapy may be more beneficial.
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Introduction
Cardiovascular disease (CVD) is the most prevalent
cause of death in women worldwide.1 The global
burden of CVD is associated with lifelong exposure to
traditional risk factors, such as hypertension, obesity,
smoking and diabetes and is strongly associated with a
prolonged unhealthy lifestyle.1,2 It has been estimated
that up to 90% of CVD risk can be explained through
traditional and modifiable risk factors.3 Over the past
decades, long-term population studies have identified
preeclampsia as one of the strongest female-specific
risk factors for CVD, associated with a two- to seven-
fold increased risk of developing ischaemic heart dis-
ease and stroke compared to women with normotensive
pregnancies.4–10
Several international obstetric guidelines recommend
screening for cardiovascular risk factors in women with a
history of preeclampsia at the age of 50 years.11–13
Leading cardiovascular prevention guidelines,
however, have not yet sufficiently implemented these
recommendations.14–17 Additionally, clinically used
treatment recommendations are based on risk-prediction
models that calculate 10-year CVD risk which are
strongly age-dependent. Shortly after pregnancy,
women will often not reach the current risk threshold
for preventive measures recommended by these guide-
lines. For example, in women with mean age of 31 years
(standard deviation (SD) 4.5), the average 10-year CVD
risk according to the Framingham Global Risk score is
1.08% (95% confidence interval (CI) of 1.04–1.12%)
whereas the recommended risk threshold is 10%.18
Current risk-based selection may therefore not be
appropriate for these young women at relatively high
but low absolute risk and a lifetime CVD risk-based
approach may be preferable.19
As the timeline during which benefits from preventive
intervention in young women accrue is lengthy, a rando-
mised or cohort setting is not feasible to assess the full
benefits of prevention. Here, a model-based approach is
valuable, even though collecting the required evidence is
challenging. Two Dutch Markov model-based studies
previously showed that early CVD prevention in
women with previous preeclampsia is likely to be cost-
effective.20,21 However, authentic long-term follow-up
data from cardiovascular screening including multiple
cardiovascular risk factor measures for each participant
were not available at the time these studies were per-
formed. Furthermore, previous studies used a cohort
model that is not able to include treatment decisions
on an individual level, which is likely to give a less real-
istic representation of clinical practice.
We present a model-based patient-level simulation
(i.e. micro-simulation) of early cardiovascular risk
screening combined with risk-based lifestyle
interventions to assess health benefits, costs and cost-
effectiveness in women with a history of preeclampsia.
We incorporated individual patient data on cardiovas-
cular risk factor measures, e.g. blood pressure level,
cholesterol level and smoking status, of an initial car-
diovascular screening six months after delivery
in women with preeclampsia and of screening after
10–20 years follow-up to estimate 10-year CVD risks.
Given the young age and the low absolute CVD risk, it
is unlikely that initial pharmaceutical treatment is
acceptable, therefore we focused on the benefits of
lifestyle interventions. A life-long horizon was applied
to capture all benefits of screening and subsequent
lifestyle interventions in these women.
Methods
A discrete time micro-simulation model was developed
to assess the impact of early preventive strategies for
CVD.22 The flowchart of this model is presented in
Supplemental Material Appendix A. The time cycle of
the model was one year. Women were followed until
death and outcomes were aggregated at population
level, i.e. total CVD events, total costs and health out-
comes, expressed in quality-adjusted-life-years
(QALYs). Supplemental Material Appendix B shows
an overview of all input parameters that were used in
the analysis. Estimates for model parameters were
based on evidence from the literature and partially on
expert opinion and consensus. Relatively wide distribu-
tions were used to properly reflect any parameter
uncertainty.
In total, we simulated a hypothetical cohort of 2000
women as the incidence of early-onset preeclampsia is
currently about 1–2% amongst a total of approxi-
mately 171,000 annual pregnancies in the
Netherlands.23,24 Women entered the simulation
model at the average age of a first pregnancy in the
Netherlands (i.e. at 30 years old).23
CVD risk estimates
As CVD risk estimates vary with age, we assumed that
CVD risk increased over time for each woman.
Published long-term data on the development of risk
factors was not available for this specific group of
women with previous preeclampsia. Therefore, we
used data from two studies in the Netherlands to cal-
culate 10-year CVD risk estimates. More information
on the used datasets can be found in Supplemental
Material Appendix C. Both studies measured cardio-
vascular risk parameters at different time intervals
after preeclampsia.
The Framingham Global Risk Score (FRS) was used
to estimate 10-year CVD risk at initial post-partum
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screening and at follow-up.25 Multiple imputation
(with 10 datasets) was performed to handle missing
predictor data using the MICE package in R.26
Imputation was based on all other available patient
characteristics, such as age, sex, blood pressure and
cholesterol levels.
Estimated CVD risk estimates and follow-up time
were not the same for all women in the two cohorts
due to differences in age at screening in both studies.
To correct for this, 10-year CVD risk estimates were
recalculated to risk estimates at the same age (for more
details see Supplemental Material Appendix D).
Usual care
Despite a national multidisciplinary guideline recom-
mending that women who experienced preeclampsia
should be offered CVD screening by their general prac-
titioner at the age of 50 years, no nationwide primary
prevention programme is currently offered in the
Netherlands.16 We therefore assumed usual care for
these women as follows. We presumed that annually
3% (range 2–4%) of all women above the age of 60
years would undergo a cardiovascular screening and
could then be identified as high-risk. Usual care applied
a risk threshold of 10% (FRS) to classify women as high
risk.27,28 Lifestyle interventions (including smoking ces-
sation, weight reduction, increasing physical activity)
were recommended to high-risk women as preventive
intervention. Medication was not used as preventive
intervention due to the young age of the women. For
those women adhering to these lifestyle change, we used
risk reduction (average 0.91, range 0.84–0.96) in the
model.29 Finally, because evidence on long-term adher-
ence rates was not available, we assumed that, on aver-
age, 20% of women stayed adherent up to 10 years after
initiation of the intervention and derived the annual
adherence rate through exponential interpolation.
Preventive strategy for CVD
The CVD prevention strategies for women after their
preeclampsia were defined as cardiovascular risk screen-
ing starting at the age of 30 or 40 years, with screening
repeated every five years and ending at the age of 55
years, followed by lifestyle advice based on these risks.
As women were young at enrolment in the model, the
current recommended generic risk threshold
(FRS> 10%) was too high, yielding hardly any
women in the high-risk category. We therefore had to
apply lower risk thresholds for the purpose of this study
(i.e. FRS> 2% and> 5%). We used the response rate of
the women invited to participate in the follow-up study
to estimate the proportion that would participate in such
a screening programme (39%, range 21–60%). Women
who had already experienced CVD (with one or more
CVD event(s)) were not considered eligible for (primary)
preventive screening, but remained in the micro-simula-
tion, potentially experiencing sequential CVD events,
until they died. Women who were assessed as low-risk
at the previous screening or who did not adhere to the
lifestyle changes were invited to the subsequent screening
event(s) after five years.
Lifestyle interventions (including smoking cessation,
weight reduction, increasing physical activity) were the
recommended preventive intervention for women clas-
sified as high risk (i.e. FRS> 2% and> 5%), consistent
with usual care. As data on adherence was lacking, we
assumed that the relative change that younger women
were adherent to lifestyle interventions was equal to the
10-year adherence of 20% in older women (see usual
care). However, given uncertainty regarding this adher-
ence rate a relative change of 0.9 (lower) to 1.1 (higher)
to this 20% adherence was used to define a plausible
range of values.
Model parameters
All model parameters are provided in Supplemental
Material Appendix B. Three CVD event categories
are distinguished in this study; coronary heart disease
(CHD), stroke, and other cardiovascular disease
(OCVD) events. The CVD events could be either fatal
or non-fatal, resulting in incorporation of six total
CVD event types. The relative occurrence of the six
event types was age-dependent and based on previous
literature (Supplemental Material Appendix B
Table 2).19,30,31 When a cardiovascular event occurred,
the CVD risk estimate was proportionally increased
(relative risk ratio 2.1, range 1.7–2.6).
Although women may experience other outcomes,
(e.g. mental or psychosocial problems) after preeclamp-
sia, little follow-up data are available regarding these
long-term outcomes and their effects (and relevance) on
quality of life (QoL).32,33 Therefore, we used QoL
values (utilities) available for women from the general
population and adjusted for age.34,35
QoL was proportionally reduced after the occurrence
of a CVD event.34,36–38 The proportional reduction in
QoL after a first CVD event depended on the CVD
event type, but remained the same for similar recurrent
CVD events. Also, the decrease in QoL after a CVD
event was lower in the first year compared to consecutive
years after the event. It was assumed that women with a
CVDeventwould receivemedication. Side-effects of pre-
scribed medication after a CVD event were assumed to
be incorporated in the disutility of the event and there-
fore not taken into account separately in the analysis.
Dutch studies and evidence from National Institute
for Health and Care Excellence were used for the
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estimation of the costs of CVD events.34,36–38 Similar to
the utilities, costs varied over the six different CVD
types. Costs for recurrent events were assumed to be
similar to costs for first-time events. Costs of the first
year after a CVD event were set higher than costs the
subsequent years. Costs of the screening programme
included a visit to the general practitioner and labora-
tory tests, and were applied to all women who partici-
pated in the screening programme. Costs of preventive
lifestyle interventions were applied to all women who
were classified as high-risk, i.e. women with CVD risk
estimates that exceeded the intervention threshold of
2% and 5%, regardless of their adherence to these life-
style interventions.
An overview of all utilities and costs together with
the distribution for the sensitivity analyses is presented
in Supplemental Material Appendix B Table 1 (rows
14–44). Following Dutch guidelines, a discount rate
of 4% for costs and 1.5% for health outcomes was
applied.39 As preventive screening, CVD events and
death due to natural causes can occur at any time
during the year (instead of only at the start or end of
a year) a half-cycle correction was applied in the model.
Cost-effectiveness analysis
The cost-effectiveness analysis was performed with the
incremental cost-effectiveness ratio (ICER) as outcome,
using a healthcare perspective. This ratio represents the
difference in lifetime costs divided by the difference
in effectiveness, i.e. health outcomes. The difference in
costs and effectiveness is defined as the difference
between the four preventive strategy (i.e. screening start-
ing at different age (i.e. 30 and 40 years) and risk levels
(i.e. 2%and5%),with subsequent lifestyle interventions)
and usual care. Probabilistic sensitivity analysis was
applied to assess how uncertainty in parameter values
resulted in uncertainty in the effect and cost outcomes.
To determine the differences between strategies, we used
4500 Monte-Carlo simulations applied to a cohort of
2000 hypothetical, unique women. Furthermore, the
probability of a preventive screening to be cost-effective
compared to alternative strategies and usual care was
estimated as a function of the willingness-to-pay
(WTP) and presented in cost-effectiveness-acceptability
curves. A commonly applied Dutch WTP threshold of
E20,000 per QALY gained is used to determine whether
a screening strategy is cost-effective or not, and to calcu-
late the incremental net health benefits (INHBs).
Lastly, we performed a value of information (VOI)
analysis to investigate the value of collecting additional
information on the parameters used to reduce the uncer-
tainty in cost-effectiveness outcomes. We used the
Sheffield Accelerated Value of Information (SAVI) tool
to estimate the expected value of perfect information
(EVPI) and expected value of partial perfect information
(EVPPI).40 The value of hypothetically resolving all
uncertainty is reflected by the EVPI whereas the
EVPPI indicates what the value is of resolving all uncer-
tainty in one parameter or a group of parameters.41
Results
Supplemental Material Appendix C shows the baseline
table of the two cohorts and the number of missing
data. Supplemental Material Appendix E shows the
authentic risk estimates of the women included in
both cohorts.
Cost-effectiveness analysis
Table 1 shows the results of the cost-effectiveness ana-
lysis using the chosen risk thresholds of 2% and 5%.
No screening has slightly lower health outcomes and
costs compared to all four preventive screening scen-
arios, i.e. 27.35 QALYs and E9426 per woman.
Screening scenarios starting at 40 years have similar
health benefits (27.41 QALYs) and the scenario with
a 5% threshold has slightly higher costs (E11,578
versus E11,561). Screening starting at 30 years with a
2% threshold has comparable health effects (27.42
versus 27.43 QALYs) and higher costs (E13,881
versus E13,078) than with a 5% threshold.
When comparing the screening strategies with each
other, preventive screening starting at 40 years and with
a 2% threshold is the ‘favourable’ preventive screening
in terms of the ICER, i.e. E34,996/QALY. Although
screening starting at 40 years with a 5% threshold
is less costly, it has less health benefits resulting in a
slightly higher ICER. Therefore, screening starting
at 40 years with a 5% threshold is dominated by screen-
ing starting at 40 years with a 2% threshold. However,
the latter strategy would not be considered cost-effec-
tive if a WTP threshold of E20,000/QALY is applied.
Screening starting at 30 years with a 5% threshold is
the second ‘best’ screening strategy in terms of cost-
effectiveness; the ICER is E101,092/QALY, compared
with screening starting at 40 years with a 2% threshold.
Screening starting at 30 years with a 2% threshold is
dominated by preventive screening starting at 30 years
with a 5% threshold due to similar health benefits but
slightly higher costs. Screening starting at 40 years with
a 5% threshold and screening starting at 30 years with a
2% threshold are therefore dominated by other strate-
gies (see strikethrough in Table 1).
Figure 1 shows the average cost-effectiveness plane
with the average health effects and costs for the four
preventive screening scenarios. Furthermore, it shows
the incremental cost-effectiveness plane where scenario
B (preventive screening starting at 40 years with a 2%
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threshold) is compared with no screening (scenario 0),
and preventive screening starting at 30 years with a 5%
threshold (scenario D). The dotted line in Figure 1 is
the WTP threshold of E20,000/QALY. The probabilis-
tic sensitivity analysis (PSA) samples of the two scen-
arios are almost similar.
Figure 2 shows the cost-effectiveness acceptability
curve. For a WTP threshold of E20,000/QALY, no
screening has the largest probability of being cost-effec-
tive, i.e. probability of 72%. For aWTP threshold above
E57,000/QALY all screening strategies are more likely
to be cost-effective than no screening, but no single strat-
egy clearly outperforms the other strategies.
VOI analysis
Table 2 shows the main results from the VOI analysis.
The VOI analysis indicates that the (annual) overall
EVPI per person affected is E5023 per person, or 0.25
QALYs per person. Furthermore, the analysis indicates
that the average single parameter 10-year CVD risk at
30 years has the largest EVPI value per person (i.e.
E1568). Further investigation of the uncertainty of
single parameters shows that collecting more informa-
tion on the average 10-year CVD risk for older women,
cost of a stroke in the first year and treatment
effectiveness has added value (see Table 2, rows 2–4).
Given that 2000 women present with previous
preeclampsia in the Netherlands per year, the popula-
tion EVPI equals E10.1 m per year.
Supplemental Material Appendix G Table 1 shows
an overview of the groups of associated parameters that
are used to estimate the group EVPPI. Collecting add-
itional information on parameters related to predicted
CVD risk (i.e. set 1), has the largest value with an
EVPPI of E1696 per person (Table 2, rows 8–10).
Supplemental Material Appendix G Table 2 shows
the results for the VOI analysis on all single parameters
(rows 2–28) and group parameters (rows 31–36).
Discussion
Short summary of findings
In this simulation study, we found that early (i.e. start-
ing at 30 or 40 years old) and repeated (every five years)
CVD risk screening and risk-based lifestyle interven-
tions after preeclampsia potentially reduces CVD risk
and improves health outcomes. However, preventive
CVD risk screening and risk-based lifestyle intervention
alone with an absolute risk threshold of 2% or 5% are
not cost-effective.
Clinical implications
Although our model estimates that early CVD risk
screening and risk-based lifestyle interventions may
Table 1. Impact (costs and health benefits) of different scenarios for cardiovascular screening every five years and lifestyle inter-
ventions in women with previous preeclampsia.
Average
costs (E)
Average
health
benefits
(QALY)
No screening 9426 27.35
Preventive screening Comparing Incremental
cost (E)
(95% CI)
Incremental health
benefits
(QALY) (95% CI)
ICER
(E/QALY)
INHB
A Screening starting
40þ 5% threshold
11,578 27.41 A to 0a
(Dominated by B)
2152
(–168–4394)
0.06
(–1.57–1.84)
37,098 –0.05
B Screening starting
40þ 2% threshold
11,561 27.41 B to 0a 2135
(–378–4405)
0.06
(–1.71–1.80)
34,996 –0.05
C Screening starting
30þ 2% threshold
13,881 27.42 C to B
(Dominated by D)
2320
(–325–5170)
0.01
(–1.72–1,76)
210,894 –0.15
D Screening starting
30þ 5% threshold
13,078 27.43 D to B 1526
(–1134–4363)
0.01
(–1.68–1.77)
101,092 –0.11
ICER: incremental cost-effectiveness ratio; INHB: incremental net health benefit; QALY: quality-adjusted-life-year.
The table is organized following the principles of the cost-effectiveness frontier: the investigated interventions are sorted based on the effectiveness
and compared amongst each other. In other words, each intervention is compared with the next best effective intervention. An intervention can be
ruled out if another intervention (or usual care) is both more effective and less costly. We have chosen to show all four interventions and strike
through the interventions that are ruled out (i.e. dominated) by another intervention.
aScenario 0 represents usual care.
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lead to very small health benefits, it is not cost-effective
(with the current model settings). Some of the following
aspects need to be considered for implications in clin-
ical practice. In our experience, offering cardiovascular
screening to women after (especially early-onset) pree-
clampsia results in relatively high percentage of women
willing to participate. Unfortunately, the current car-
diovascular screening for these women takes place in
the hospital which may result in a lower participation
rate of these women, i.e. mothers with young children
who do not attend the half day of in-hospital screening.
Although specific risk factors, such as familiar hyper-
cholesterolaemia, should be treated by a vascular spe-
cialist, implementation of screening and lifestyle
interventions in Dutch primary care would be more
efficient. The Dutch general practitioner (GP) system
is well structured and easily accessible, but such a
system may not be available in some other countries.
In addition, our model only included the health
effects gained by reducing cardiovascular outcomes. It
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Figure 1. Results of the probabilistic sensitivity analyses (PSAs). The average health benefits and costs are shown in the cost-
effectiveness plane for all four screening scenarios (a). The difference in benefits and costs of promising screening scenarios are shown
in the incremental cost-effectiveness plane with a willingness-to-pay (WTP) threshold of E20,000/quality-adjusted-life-year (b).
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is likely that the proposed lifestyle interventions (i.e.
weight reduction, smoking cessation and improving
physical activity patterns) have an additional health
benefit in preventing other (non-cardiovascular)
health problems, such as preventing joint problems in
obese patients and chronic pulmonary problems in
smokers. Additionally, the lowering of risk factors
will likely reduce risk of other long-term events, such
as hypertension and subsequent renal failure, which
were currently not incorporated in the model. This
may result in further lengthening of life in good
health as women age. Taking the facts together we
anticipate that, in a real-world setting, more women
would, and could, benefit from early cardiovascular
screening and intervention when they have experienced
preeclampsia.
Comparison with other studies
Two Dutch studies showed the potential benefits of
early hypertension and metabolic syndrome detection,
including medication and/or lifestyle intervention, in
women with a history of preeclampsia.20,21 These stu-
dies concluded that CVD prevention in women with
preeclampsia is likely to be cost-effective or may save
costs without affection quality of life for the first 10–20
years. The difference in results and conclusions of the
current study and the two previous studies may be
related to the use of medication as an intervention strat-
egy following CVD screening. As an intervention
targeting a change in lifestyle (eating, drinking, smok-
ing and physical activity habits) takes more time and it
is more expensive, than starting a (relatively cheap)
drug.
Both previous studies use blood pressure
(140/99mm Hg) for treatment selection whereas the
treatment selection of our study was risk-based.
Furthermore, the published studies used a Markov
model with a number of ‘health states’ with fixed tran-
sitions between states, whereas we used an individual
patient-level model. This provided the opportunity to
include CVD risk factors, simulated events and out-
comes on an individual level which moves closer to
individualised care. For the current study, all individual
CVD risk factors were combined in one risk estimate
and the change in expected risk was modelled over
time. For future research, it is possible to further
detail individual risk assessment by also incorporating
the assessed CVD risk factor levels per individual.
Furthermore, the use of real-world follow-up data of
women at 10–20 years post-preeclampsia to estimate
the CVD risks and subsequent correlation between
risk profiles likely has led to more accurate and realistic
results, compared with studies making assumptions on
risk development over time.
Strengths
The strength of this study is the incorporation of actual
risk factor data from women who underwent
Table 2. Summary of main results from value of information analysis (see Supplemental Material Appendix F Table 2 for the complete
set of results).
Per person
EVPPI (E)
Standard
error
Indexed
to overall
EVPI¼ 1.00
EVPPI for
Netherlands
per year (E)
EVPPI for
Netherlands
over 5 years (E)
Single parameter EVPPI
Average 10-year CVD risk at age 30 1567.6 129.4 0.3 3,135,000 15,680,000
Average 10-year CVD risk at age 80 259.7 98.1 0.1 519,400 2,597,000
Cost of stroke event (first year) 44.3 40.1 0.0 88,630 443,100
Relative risk of CVD with preventive
intervention versus without intervention
21.0 37.1 0.0 41,930 209,700
Utility of other CVD event (sequential year) 12.2 37.0 0.0 24,300 121,500
Group parameter EVPPI
Set 1 – predicted CVD risk
The following parameters were grouped:
average 10-year CVD risk at 30 years;
average 10-year CVD risk at 80 years;
marginal correlation between risk
profiles (per 10 years).
1696.3 134.3 0.3 3,392,611 16,963,053
CVD: cardiovascular disease; EVPI: expected value of perfect information; EVPPI: expected value of partial perfect information.
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cardiovascular screening at several time points after
preeclampsia. These data gave insight in the risk distri-
bution among women with preeclampsia for different
age categories. Furthermore, these data were used to
estimate the correlation between 10-year risk estimates
within women over time. A micro-simulation model was
used to assess the long-term benefits of CVD risk screen-
ing combined with risk-based lifestyle advice in young
women. The use of a model with a lifetime horizon is
important, as age is a key factor in development of
CVD. Moreover, the first manifestation of CVD may
take two to four decades following preeclampsia.42 We
postulate that this model, with simple adjustments, can
be applied to assess the potential benefits of early CVD
risk screening combined with any subsequent risk-based
intervention in other populations with (female) specific
risk factors, such as women with polycystic ovarian syn-
drome (PCOS) or premature ovarian insufficiency (POI)
or migraine with aura.43,44 Use of such models may pro-
vide information to make evidence-based guidelines and
decisions for establishing cardiovascular prevention
programmes for women with a medical history, while
the evidence of intervention studies in these specific
female subgroups is still lacking.
Limitations
Since evidence on several parameters within the model
was lacking, certain assumptions had to be made and
extrapolation was required. To properly reflect the
uncertainty in the parameters, we allowed relatively
wide distributions for most parameters and incorpo-
rated expert opinions on behaviour, risks and benefits
of interventions in this specific group of women.
Also, data on CVD risk after 80 years of age was lack-
ing and this risk was therefore kept constant beyond
this age.
Furthermore, we considered only preventive inter-
vention of lifestyle changes for both young and older
women. This approach may not be realistic in clinical
practice since lifestyle modification is known to be dif-
ficult to achieve and the effectiveness is rather
low.29,45,46 Additionally, lifestyle interventions were
not combined with any drug therapies, such as lipid-
lowering or antihypertensive medication. However, as
women were young during the post-partum risk evalu-
ation, the use of life long drug therapy from a young
age onwards is perhaps unrealistic. Nevertheless, some
young women may be willing to take medication when
becoming aware of their CVD risk after having suffered
from preeclampsia.47 For example, the proportion of
women that answered ‘yes’ to the question ‘Do you
have a prescription of preventive medication?’ in the
initial cardiovascular screening is around 19% (see
Supplemental Material Appendix C). Additionally,
a notable proportion had health complaints due to
hypertension shortly after pregnancy, making it more
likely that they would be willing to use medical therapy,
even at their young age.47,48 Further research on the
optimal (age-dependent) combination of lifestyle inter-
ventions, preventive medication or other preventive
interventions (e.g. self-monitoring with e-health appli-
cations), and the actual adherence to these interven-
tions should be conducted.49
Recent CVD preventive guidelines have supported
treatment of young individuals even though evidence
from randomised or cohort studies for these implemen-
tations is not yet available.50 Taking these possibilities
into consideration, the assumption that women
in our ‘no screening’ scenario are not identified,
or treated, before the age of 60 years may lead to
an underestimation of the benefits of usual care in
reality. This needs to be evaluated further and may
need to be taken in to account when performing similar
research in the future.
Also, we estimated CVD risk with FRS, which might
not be suitable for young women with previous pree-
clampsia. Age is a strong contributor to this score and
although women with previous preeclampsia develop
CVD as soon as 10 years earlier, FRS is often not
raised above the indicative 10% threshold soon after
pregnancy.11,12 Unfortunately, there is no CVD risk
score available that includes a (complicated) obstetric
history as predictor.
Additionally, we used data from women with both
late and early onset preeclampsia for this study.
Although this gives a relevant overview of women
with previous preeclampsia, this may underestimate
the possible benefits of screening for women with a
severe, or early, phenotype. Results from our analysis
can therefore also not directly be extrapolated to
women with other pregnancy complications (or specific
phenotypes of preeclampsia), as the preventive effects
are likely to differ in those women. Lastly, we were not
able to consider comorbidities or the occurrence of
other diseases, like auto-immune disorders or impaired
memory, associated with preeclampsia and affecting the
outcome and quality of life in these women.51
Conclusion
Our model-based impact assessment demonstrates that
CVD risk screening combined with risk-based lifestyle
interventions (without preventive treatment initiation)
to prevent CVD in women with a history of preeclamp-
sia is not cost-effective. This study shows that for estab-
lishing a beneficial cardiovascular prevention program
for women starting early after experiencing preeclamp-
sia, a more effective intervention or combination of
interventions may be more realistic.
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